Booth Bruce sold $44.2M of KYMR (indirect holdings)
Booth Bruce sold 466,457 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $94.84 ($90.38–$102.48, $44.24M total) across 28 trades over 2026-06-17 to 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may reassess near-term sentiment around KYMR, but the disclosure does not include new operational, clinical, or financial guidance—so fundamental repricing is less likely absent other catalysts.
Market read
Material insider selling is newly disclosed, but the 10b5-1 structure suggests limited informational content beyond scheduled liquidity.
What to watch
Because the trades span multiple prices ($90.38–$102.48), the sale may reflect execution mechanics rather than a single directional view.
Background
The filing is an SEC Form 4 insider transaction by director Booth Bruce, reported as an indirect holding sale under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Kymera Therapeutics director Booth Bruce sold $44.24M of KYMR via a 10b5-1 plan across 28 trades at $90.38–$102.48.
Likely limited/short-lived impact; any reaction should fade unless accompanied by other company-specific catalysts.
Form 4 is a primary disclosure and the sale size is material, but the presence of a 10b5-1 plan reduces inference about new negative information.
Market effects
No direct sector read-across; this is company-specific insider liquidity disclosure.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can be purely scheduled liquidity; the post-transaction holdings remain substantial (617,663 shares), so the signal may be overstated.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider sale; director Booth Bruce sold shares under a 10b5-1 plan.
- insiderBooth Bruce
Director who executed open-market sales totaling $44.24M (indirect holdings) during 2026-06-17 to 2026-06-22.
